All In Biotech

NDA 020699 · Upjohn

Effexor Xr

Venlafaxine Hydrochloride · Oral

Last checked: Nov 20, 2026Latest source record: Aug 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1997

Oct 20, 1997

Approved uses

11

Original approval plus efficacy supplements

Registered trials

231

58 Phase 3, 14 recruiting

FAERS reports

76,828

52,184 serious, 5,190 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1) ] . Effexor XR is not approved for use in pediatric patients [see Use in Specific Populations (8.4) ] . WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. • Increased risk of suicidal thoughts and behavior in pediatric patients and young adults taking antidepressants. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors ( 5.1 ). • Effexor XR is not approved for use in pediatric patients ( 8.4 ).

What it is approved for

From the label in effect Aug 15, 2023.

Effexor XR is indicated in adults for the treatment of: • Major Depressive Disorder (MDD) [see Clinical Studies (14.1) ] • Generalized Anxiety Disorder (GAD) [see Clinical Studies (14.2) ] • Social Anxiety Disorder (SAD) [see Clinical Studies (14.3) ] • Panic Disorder (PD) [see Clinical Studies (14.4) ] Effexor XR is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of adults with: • Major Depressive Disorder (MDD) ( 1 ) • Generalized Anxiety Disorder (GAD) ( 1 ) • Social Anxiety Disorder (SAD) ( 1 ) • Panic Disorder (PD) ( 1 )

Mechanism: The mechanism of action of venlafaxine in the treatment of MDD, GAD, SAD, and PD is unclear, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • EFFEXOR XR · VENLAFAXINE HYDROCHLORIDE EQ 150MG BASE · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • EFFEXOR XR · VENLAFAXINE HYDROCHLORIDE EQ 75MG BASE · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • EFFEXOR XR · VENLAFAXINE HYDROCHLORIDE EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE, EXTENDED RELEASE, ORAL · Discontinued
  • EFFEXOR XR · VENLAFAXINE HYDROCHLORIDE EQ 37.5MG BASE · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Venlafaxine" as an intervention, any sponsor and status, largest first.

All 231 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective6,585
  • nausea6,292
  • fatigue5,249
  • headache5,249
  • depression4,457
  • dizziness4,438
  • anxiety4,358
  • pain3,996
  • off label use3,747
  • insomnia3,481
  • diarrhoea3,363
  • malaise3,192

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042,403
20052,828
20062,585
20072,461
20082,413
20092,745
20104,161
20113,674
20124,406
20133,653
20143,528
20154,697
20165,188
20174,024
20184,040
20194,053
20203,433
20212,965
20223,116
20232,982
20243,043
20252,597
20261,832

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Effexor XR (Venlafaxine HCl)

2024 spending

$23.8M

Beneficiaries

2,814

16,997 claims

Per beneficiary

$8,449

$18.84 per unit

View as table
YearSpending
2020$30,535,488
2021$27,166,106
2022$26,028,688
2023$26,196,304
2024$23,774,435

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,067 on PubMed

Sponsor: Upjohn

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.